4-Phenyl-4H-pyrans as IKCa channel blockers

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 16, 2003, Pages 2637-2639

  Urbahns, Klaus ^a,b   Horváth, Ervin ^a   Stasch, Johannes Peter ^a   Mauler, Frank ^a  

^a BAYER AG   (Germany)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM ION CHANNEL BLOCKER; PYRAN DERIVATIVE; RAC 11; RAC 6; RAC 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBDURAL HEMATOMA;

EID: 0038487765     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00560-2     Document Type: Article

References (26)

1. Ca.
2. (a) Logsdon N.J., Kang J., Togo J.A., Christian E.P., Aiyar J. J. Biol. Chem. 272:1997;32723 (b) Joiner W.J., Wang L.Y., Tang M.D., Kaczmarek L.K. Proc. Natl. Acad. Sci., U.S.A. 94:1997;11013.
3. (a) Logsdon N.J., Kang J., Togo J.A., Christian E.P., Aiyar J. J. Biol. Chem. 272:1997;32723 (b) Joiner W.J., Wang L.Y., Tang M.D., Kaczmarek L.K. Proc. Natl. Acad. Sci., U.S.A. 94:1997;11013.
4. Gardos G. Biochim. Biophys. Acta. 30:1958;147.
5. NIH Consensus Development Panel on Rehabilitation of Persons with TBI. JAMA 1999, 282, 974.
6. (a) Schwab A., Am J. Physiol. Renal Physiol. 280:2001;F739 (b) Schwab A. Curr. Res. Ion Channel Mod. 3:1998;126.
7. (a) Schwab A., Am J. Physiol. Renal Physiol. 280:2001;F739 (b) Schwab A. Curr. Res. Ion Channel Mod. 3:1998;126.
8. Khanna R., Roy L., Zhu X., Schlichter L.C. Am. J. Physiol. Cell. Physiol. 280:2001;C796.
9. Ellory J.C., Culliford S.J., Smith P.A., Wolowyk M.W., Knaus E.E. Br. J. Pharmacol. 111:1994;903.
10. (a) Goldmann S., Stoltefuß J. Angew. Chem. 103:1991;1587 (b) Triggle D.J., Langs D.R., Janis R.A. Med. Res. Rev. 9:1989;123.
11. (a) Goldmann S., Stoltefuß J. Angew. Chem. 103:1991;1587 (b) Triggle D.J., Langs D.R., Janis R.A. Med. Res. Rev. 9:1989;123.
12. Wolinsky J., Hauer H.S. J. Org. Chem. 34:1969;3169.
13. 3); 4.82 (s, 1H, H-C(4)); 7.48-7.51 (m, 3H).
14. For further details of the syntheses, see: Urbahns, K.; Mauler, F.; EP 0758648, 1997; Chem. Abstr. 1997, 247810.
15. Tas P.W.L., Kress H.G., Koschel R. Neurosci. Lett. 94:1988;279.
16. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
17. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
18. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
19. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
20. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
21. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
22. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
23. - channel (TBPS): Lewin, A.H.; De Costa, B.R.; Rice, K.C.; Skolnick, P. Mol. Pharmacol. 1989, 35, 189. Specific binding to rat cerebral cortex was below 10% in all experiments at 100 nM of rac-11.
24. Wegner M., Ganten D., Stasch J.-P. Hypertens. Res. 19:1996;229.
25. Miller J.D., Bullock R., Graham D.I., Chen M.H., Teasdale G.M. Neurosurg. 27:1990;433.
26. The calculated log P values were obtained using the ACD Lab web service, Advanced Chemistry Development, Inc., Toronto, Canada. The following clogP values were obtained for 5: 4.25, rac-6: 4.78; 8: 5.31; 12: 6.38; 13: 7.44.